Evidence map›Paper›PMID 41783625›Full record

ArticleThe World Allergy Organization journal2026

Association of muscle instability and long-term prophylaxis in hereditary angioedema.

Eleanor Hollers, Yunting Yu, James Sheetz, Kristina Richwine, Kara Grim, Rita Germak-Sovereign, Long Luong, Hirofumi Hitomi, Taha Al-Shaikhly, Timothy Craig

Abstract read
In one paragraph

Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eleanor HollersDepartment of Medicine, Section of Allergy, Asthma & Immunology, Pennsylvania State University, Hershey, PA 17033, USA.
Yunting YuDepartment of Medicine, Section of Allergy, Asthma & Immunology, Pennsylvania State University, Hershey, PA 17033, USA.
James SheetzThomas Jefferson University, Sidney Kimmel Medical College, Philadelphia, PA, 19107, USA.
Kristina RichwineDepartment of Medicine, Section of Allergy, Asthma & Immunology, Pennsylvania State University, Hershey, PA 17033, USA.
Kara GrimDepartment of Medicine, Section of Allergy, Asthma & Immunology, Pennsylvania State University, Hershey, PA 17033, USA.
Rita Germak-SovereignDepartment of Medicine, Section of Allergy, Asthma & Immunology, Pennsylvania State University, Hershey, PA 17033, USA.
Long LuongDepartment of iPS Stem Cell & Regenerative Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
Hirofumi HitomiDepartment of iPS Stem Cell & Regenerative Medicine, Kansai Medical University, Hirakata, Osaka, Japan.
Taha Al-ShaikhlyDepartment of Medicine, Section of Allergy, Asthma & Immunology, Pennsylvania State University, Hershey, PA 17033, USA.
Timothy CraigDepartment of Medicine, Section of Allergy, Asthma & Immunology, Pennsylvania State University, Hershey, PA 17033, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hereditary angioedema (HAE) types 1 and 2 are caused by C1 inhibitor deficiency or dysfunction, leading to increased prekallikrein activity and bradykinin production. HAE causes vasodilation and edema resulting in obstruction of the upper airway, gastrointestinal symptoms, and skin swelling. Evidence of involvement of other organ systems has been sparse. Herein, we demonstrate evidence of creatinine kinase (CK) elevation in HAE patients suggesting an effect of bradykinin on skeletal muscle with subsequent improvement with long term prophylaxis (LTP). Methods: CK levels from participants with type 1 or 2 HAE enrolled in the Phase 2 and 3 clinical trials evaluating the safety and efficacy of donidalorsen for LTP in patients with HAE, was measured at baseline (before treatment initiation) and Week 17 (for participants enrolled in Phase 2 Study) and Week 25 (for participants enrolled in Phase 3 study). Mixed effect model with repeated measures was used to assess the influence of time and treatment (donidalorsen vs. placebo) on serum CK levels. Results: CK levels were available from 20 patients enrolled in the Phase 2 study and the mean CK level was numerically lower by Week 17; however, these results were not statistically significant. Among the 90 participants enrolled in the Phase 3 study who had CK levels checked at baseline and Week 25, a significantly lower CK level at Week 25 was observed among those receiving Q4W donidalorsen, but not among those receiving donidalorsen Q8W or placebo. Conclusion: Bradykinin appears to cause instability of skeletal muscle, causing CK release with even minor exercise. The effect of increases in bradykinin in HAE on muscle needs further research but may account for some of the atypical HAE symptoms patients often describe and which are noted in quality-of-life assessments. LTP, therefore, may confer additional benefits beyond reduction of HAE symptoms, potentially contributing to stabilization of skeletal muscle and improvement of fatigue and weakness.

Indexed as

CPKCreatine kinaseFatigueHereditary angioedemaMuscleProphylaxis

Identifiers

PMID41783625
PMCPMC12955664

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.